新辅助治疗在胰腺癌中的应用现状和争议

Current status and controversy of neoadjuvant therapy in pancreatic cancer

胰腺癌因具有高侵袭性、高转移性、高复发率等特点被认为是恶性程度极高的消化道肿瘤。近年来新辅助治疗给胰腺癌的治疗带来了新的曙光,如今新辅助治疗在胰腺癌的价值已被广泛认可,但缺乏特异性方案,各类方案孰优孰劣尚无定论,可联合影像学、功能学和生物学标记物评估新辅助治疗的效果。

Pancreatic cancer is considered to be the most malignant digestive tract tumor due to its high invasiveness,metastasis and recurrence rate.In recent years,neoadjuvant therapy has brought new insights to the treatment of pancreatic cancer.To date,the value of neoadjuvant therapy in pancreatic cancer has been widely recognized,but there is a lack of specific regimens.The superiority and inferiority of various regimens are still uncertain,therefore,the efficacy of neoadjuvant therapy can be evaluated combined with imaging,functional and biological markers.